Rita Cherradi

Motics AI empowers clinics to scale, without scaling their costs, by automating and interlinking administrative tasks across clinical note-taking, phone calls, billing, communication and clinical audit. Clinics using Motics benefit from streamlined workflows, deep EHR integration and more clinical time to provide better patient experiences. Supported by Morgan Stanley, Impact Shakers, Techstars and more.

Perineal tearing affects up to 90% of women birthing vaginally. It is painful and costly, estimated at over $10 billion annually in the US alone and for too long it has been accepted as an inevitable part of childbirth. We dont accept that. Peripear is developing a wearable medical device that translates an evidence-based midwifery intervention, warm compress application during the second stage of labour, into a consistent, hands-free clinical tool which is designed to reduce perineal tearing at the moment it most commonly occurs. We are backed by InnovateUK, 85% through our pre-seed round and in active conversation with US health systems about pilot partnerships. Our functional prototype is complete and was built in under two months. Behind Peripear are two founders with complementary depth. Nina brings 14 years of NHS and private midwifery practice with direct experience of the clinical gap this device is designed to address. Eviatar brings over a decade of healthtech leadership, having raised more than $75M and scaled MedTech companies from concept to market as CXO, supported by a PhD from the University of Cambridge and a visiting scholarship at MIT. We are building toward US hospital pilots, clinical evidence generation and long-term integration into standard perinatal care. If you are an investor, clinical innovator or health system leader who believes maternity care deserves better tools, wed always welcome a conversation.

Our mission at Biographica is to accelerate crop improvement, to feed a growing population on a changing planet. The world is facing a food security crisis. We must produce more food in the next 50 years than in the previous 10,000 combined - and at a time when climate change is reducing crop productivity. Gene-editing represents a significant opportunity to address this challenge, by enabling rapid and precise enhancement of crop varieties. However, identifying which genes to edit and how remains a major bottleneck, costing millions of dollars, taking over 2 years, and failing more than 95% of the time. At Biographica were revolutionising this process, by harnessing recent developments in gene-editing, high-throughput sequencing and biology-aware machine learning. Our platform combines graph ML-based, in silico modelling with in vivo validation to rapidly pinpoint genomic modifications that can improve any trait, in any crop. Gene-editing is the future of food. With our platform, we intend to become the gene discovery engine behind the crops of the future. For any enquiries reach out at hello@graphica.bio, and explore our open roles at: https://biographica.recruit.charliehr.com/careers

52North is a medical technology company on a mission to make urgent care pathways safer and more effective. Awarded breakthrough status for its first product Neutrocheck® by the UK Government in 2024, 52North builds in vitro diagnostic and digital solutions to transform patient journeys in urgent care. Its award-winning, multidisciplinary team is based in Cambridge, UK. 52North is backed by leading UK and US hospital venture funds, Meridian Health Ventures and Cedars-Sinai Intellectual Property company, and other partners, including the University of Cambridge and Macmillan Cancer Support.

We monitor eye health at home. We are developing the first digital bio markers of the eye, by tracking visual interactions with smart devices. Our vision is to predict eye and wellness disorders ahead of time.

Founded by Gillian Anderson, G Spot is the sweet spot between taste and functionality. Our drinks are refreshing, natural, and filled to the brim with life-enhancing adaptogens and nootropics. A simple mix of what we know tastes good, enhanced with what we know does good. #ifoundmygspot #tastesfxckinggood

Fides is taking Corporate Governance to the 21st century! ⚖️ We are making it easier for companies to comply with, digitally execute and track their legal obligations across different entities and boards in various jurisdictions. 📅 Keep an overview of duties, deadlines and tasks in all entities and committees. 📝 Orchestrate, execute and document resolutions, approvals and meetings. 🔗 Create a revision-proof audit trail of any duty fulfilled and decision made. We know you have good intentions. You just need to be able to prove them. Our customers include big corporates, family-owned businesses and PE and VC funds. Any company that has lots of subsidiaries to manage will feel massive value added from implementing Fides. Dont hesitate and let us help you make your life easier. Book a demo today! Privacy Policy: https://www.fides.technology/privacypolicy?hsLang=en

Transforming the way we consume fashion, By Rotation is the worlds largest shared wardrobe. Rent, lend and resell quality fashion with our community. #SustainableFashion #CircularFashion

Unibloom offers sustainability managers a comprehensive solution to streamline their efforts, give head space to look ahead and drive impactful change within their organisations by automating & translating complex modelling & data to easy understandable impact for each business owner & stakeholder. Our platform enables you to: Centralise Integration: Unibloom brings together all your teams, projects, and budgets in one place, fostering collaboration and transparency. Automate Processes: Say goodbye to manual calculations, email & chasing data & projects in power points. Unibloom automates modelling and calculations for packaging, energy, ingredients, and circularity initiatives, allowing for customisable scenarios to optimise ROI on emissions, water, waste, land-use & deforestation reduction and combine the model with investments & cost savings. Align with Targets: Stay on track with your Science Based Targets, FLAG and Business Targets. Unibloom is cross-functional and aligned with GHG protocoll, CSRD and SBTi frameworks, facilitating progress towards your commitments. Eliminate Pain Points: No more spreadsheet errors or misaligned targets. Unibloom streamlines workflows, eliminates silos, and provides real-time tracking for all your sustainability projects and keep you stay head of customers, regulations & employees requirements for transparency & actions. Tailored Solutions: Developed in collaboration with consumer goods industry experts, the fintech derivative & data scientist experts, Unibloom is tailored to meet the unique needs of sustainability teams and key stakeholders, aligning seamlessly with industry workflows and regulatory frameworks. Experience the power of Unibloom for yourself. Book a demo with Anna Sandgren today: calendly.com/anna-sandgren

Motics AI empowers clinics to scale, without scaling their costs, by automating and interlinking administrative tasks across clinical note-taking, phone calls, billing, communication and clinical audit. Clinics using Motics benefit from streamlined workflows, deep EHR integration and more clinical time to provide better patient experiences. Supported by Morgan Stanley, Impact Shakers, Techstars and more.

Perineal tearing affects up to 90% of women birthing vaginally. It is painful and costly, estimated at over $10 billion annually in the US alone and for too long it has been accepted as an inevitable part of childbirth. We dont accept that. Peripear is developing a wearable medical device that translates an evidence-based midwifery intervention, warm compress application during the second stage of labour, into a consistent, hands-free clinical tool which is designed to reduce perineal tearing at the moment it most commonly occurs. We are backed by InnovateUK, 85% through our pre-seed round and in active conversation with US health systems about pilot partnerships. Our functional prototype is complete and was built in under two months. Behind Peripear are two founders with complementary depth. Nina brings 14 years of NHS and private midwifery practice with direct experience of the clinical gap this device is designed to address. Eviatar brings over a decade of healthtech leadership, having raised more than $75M and scaled MedTech companies from concept to market as CXO, supported by a PhD from the University of Cambridge and a visiting scholarship at MIT. We are building toward US hospital pilots, clinical evidence generation and long-term integration into standard perinatal care. If you are an investor, clinical innovator or health system leader who believes maternity care deserves better tools, wed always welcome a conversation.

Our mission at Biographica is to accelerate crop improvement, to feed a growing population on a changing planet. The world is facing a food security crisis. We must produce more food in the next 50 years than in the previous 10,000 combined - and at a time when climate change is reducing crop productivity. Gene-editing represents a significant opportunity to address this challenge, by enabling rapid and precise enhancement of crop varieties. However, identifying which genes to edit and how remains a major bottleneck, costing millions of dollars, taking over 2 years, and failing more than 95% of the time. At Biographica were revolutionising this process, by harnessing recent developments in gene-editing, high-throughput sequencing and biology-aware machine learning. Our platform combines graph ML-based, in silico modelling with in vivo validation to rapidly pinpoint genomic modifications that can improve any trait, in any crop. Gene-editing is the future of food. With our platform, we intend to become the gene discovery engine behind the crops of the future. For any enquiries reach out at hello@graphica.bio, and explore our open roles at: https://biographica.recruit.charliehr.com/careers

52North is a medical technology company on a mission to make urgent care pathways safer and more effective. Awarded breakthrough status for its first product Neutrocheck® by the UK Government in 2024, 52North builds in vitro diagnostic and digital solutions to transform patient journeys in urgent care. Its award-winning, multidisciplinary team is based in Cambridge, UK. 52North is backed by leading UK and US hospital venture funds, Meridian Health Ventures and Cedars-Sinai Intellectual Property company, and other partners, including the University of Cambridge and Macmillan Cancer Support.

We monitor eye health at home. We are developing the first digital bio markers of the eye, by tracking visual interactions with smart devices. Our vision is to predict eye and wellness disorders ahead of time.